Please join us and have your say! 
Governments are making decisions about myeloma drug access, be sure your voice is heard by completing one or both of the short surveys below – based on your treatment history, you may qualify for both surveys.
Survey 1 is for:
People living with myeloma who are not eligible for an autologous stem-cell transplant (who have NOT had a transplant as a course of therapy to treat their Myeloma), as well as their caregivers, who have used the following treatment combinations:
 
  1. bortezomib (Velcade®), melphelan and prednisone (VMP) with or without daratumumab (Darzalex®)
  2. cyclophosphamide, bortezomib (Velcade®), and dexamethasone (CyBorD) with or without daratumumab (Darzalex®)
  3. lenolidomide (Revilimid®) and dexamethasone with or without bortezomib (Velcade®)
Survey 2 is for:
People living with myeloma, and their caregivers, who have used Ninlaro® (ixazomib) in combination with lenalidomide (Revlimid®) and dexamethasone to treat their myeloma .  
Myeloma Canada will provide patient and caregiver input to the pan Canadian Oncology Drug Review (pCODR) and the Institut National d’excellence en Santé et en Services Sociaux (INESSS) process for myeloma treatment regimens that will be reviewed over the next few months. pCODR is the national agency that makes funding recommendations to provinces on oncology drugs approved for sale in Canada and INESSS does the same for the province of Quebec. 
 
As always, your input is extremely important and, although there is no guarantee, it may help to improve the availability and access to important new myeloma drugs for patients across Canada.
 
The patient surveys should take about 15 minutes and the caregiver about 5 minutes. We ask that you complete the survey  Monday, October 1, 2018 .
 
If you have any questions about this survey, please write to  info@myeloma.ca  and include Patient or Caregiver Survey in the subject line.
Privacy policy : All survey data are being collected by Myeloma Canada, a national, not for profit, charitable, patient-led group. To ensure patient and caregiver privacy and confidentiality, individual responses will not be identifiable. It is important to note that selected quotations may be used in the final report to pCODR and INESSS without reference to patient or caregiver name or any other identifying information.
 
Thank you for your participation!